Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2025 13:39 ET | Quelle: Spherix Global Insights

Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights

EXTON, PA, April 30, 2025 (GLOBE NEWSWIRE) -- The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis (LN) have led specialists to reconsider their...
10. Oktober 2024 10:28 ET | Quelle: Spherix Global Insights

Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
13. Oktober 2023 05:40 ET | Quelle: UXUY

UXUY Implements Bitcoin Lightning Node to Serve Multi-Chain Trading for Taproot Assets

Singapore, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Today 13th of October, 2023, the next-generation decentralized trading platform UXUY will officially implement the Bitcoin Lightning Network node named...
26. Februar 2019 16:07 ET | Quelle: Equillium

Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...